With an increased interest in the epigenetic origins of psychiatric disorder, there has been a corresponding increase in the number of studies examining histone deacetylase (HDAC) inhibitors and gene expression in the central nervous system. HDAC inhibitors have been regarded as important targets in psychotropic drug development. With a professional specialist team and advanced drug development platform, Creative Biolabs provides a full range of target development services to meet global researchers' detailed requirements.
Introduction to HDAC Inhibitors
Histone acetylation and DNA methylation are two well established epigenetic modifications that are targeted by currently available drugs known as HDAC inhibitors and DNA methyltransferase inhibitors. Several pharmacological therapies using HDAC inhibitors have been beneficial in various experimental models of brain diseases. Evidence suggests that targeting HDACs and histone acetylation might prove advantageous for seizure disorders, amyotrophic lateral sclerosis, Alzheimer's disease, RubinsteinTaybi syndrome, spinal muscular atrophy, Rett syndrome, stroke, Fragile X syndrome, and Huntington's disease, among others. These drugs also hold promise for therapy relevant to several psychiatric disorders, including schizophrenia, depression, drug addiction, and anxiety disorders. For these reasons, HDACs represent attractive molecular targets for the treatment of several neurological and psychiatric diseases.
HDAC Inhibitors and Psychiatric Disorders
Currently, available HDAC inhibitors can be divided into four classes based on their chemical structures. This classification includes hydroxamates, short-chain fatty acids and benzamides. Among these, short-chain fatty acids and benzamides are reported as potential psychotropic drugs.
These inhibitors include compounds with rather simple structures, such as valproic acid, phenylbutyrate, and butyrate. Among these, sodium butyrate has diverse properties and has been shown to exert antidepressant properties in the mouse brain. Moreover, sodium butyrate has been shown to induce neurogenesis in the rat brain after cerebral ischemia. Valproic acid (VPI, 2-propyl pentanoic acid, Divalproex) is an established central nervous system drug that has been used as an anticonvulsant, mood stabilizer, and adjuvant treatment for schizophrenia.
Among the benzamide HDAC inhibitors, both MS-275 (also known as SNDX-275) and CI-994 are currently in clinical trials for the treatment of cancer. Recently, MS-275 has garnered some attention because of its ability to inhibit HDACs in the brain. The benzamide HDAC inhibitors may be useful in selectively activating promoters that may be insufficiently expressed in schizophrenia and other psychiatric conditions. Similar to the antidepressant properties of sodium butyrate, MS-275 also shows promise in the search for drugs that might be useful for treating depression.
Services at Creative Biolabs
With proven expertise and a mature technology platform in psychotropic drug development, Creative Biolabs aspires to become a global-leading, customer-responsive, and fully integrated biopharmaceutical company that offers target discovery, preclinical model development, validation, qualification, and any other aspects in psychotropic drug development. Our scientists have specialized in HDAC inhibitors for a long time and thus are capable of providing high-quality relative target development services.
HDAC inhibitors as important psychotropic targets have aroused researchers' interests. As an industry-leading biopharmaceutical company, Creative Biolabs is committed to offering customer-satisfied target development services through our reliable professional experience. If you have any questions, please feel free to contact us.
For Research Use Only.
